Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Capital Expenditures (2016 - 2022)

Edesa Biotech's Capital Expenditures history spans 10 years, with the latest figure at -$41.0 for Q3 2022.

  • For Q3 2022, Capital Expenditures rose 97.2% year-over-year to -$41.0; the TTM value through Sep 2022 reached $5656.0, down 7.97%, while the annual FY2022 figure was $5656.0, 7.97% down from the prior year.
  • Capital Expenditures for Q3 2022 was -$41.0 at Edesa Biotech, down from $1358.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $171124.0 in Q1 2018 and bottomed at -$1464.0 in Q3 2021.
  • The 5-year median for Capital Expenditures is $2963.0 (2021), against an average of $14932.9.
  • The largest annual shift saw Capital Expenditures surged 303.1% in 2018 before it crashed 136.32% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $5666.0 in 2018, then tumbled by 59.99% to $2267.0 in 2019, then plummeted by 49.93% to $1135.0 in 2020, then surged by 176.65% to $3140.0 in 2021, then plummeted by 101.31% to -$41.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Capital Expenditures are -$41.0 (Q3 2022), $1358.0 (Q2 2022), and $1199.0 (Q1 2022).